Abstract:Topic: 16. Myeloproliferative neoplasms - Clinical Background: Essential thrombocythemia (ET) was characterized by aberrant hematopoietic proliferation with the risk of myelofibrosis (MF) progression. Red blood cell distribution width (RDW) and ASXL1 as a chromatin modifier may be associated with MF progression. However, there is no report of their influences on the MF progression of ET patients. Aims: To analyze the prognostic factors of the MF progression of ET patients. Methods: We concluded a retrospective study of 354 ET patients from October 2014 to December 2022 in the Fourth Affiliated Hospital and the First Affiliated Hospital of Zhejiang University School of Medicine. Patients were divided into the non-myelofibrosis (non-MF) progression group and the myelofibrosis (MF) progression group. Patients with incomplete information from laboratory tests and medical records were excluded. This study was approved by the Ethics Committee of the Fourth Affiliated Hospital and the First Affiliated Hospital of Zhejiang University School of Medicine. Statistical analyses were performed using SPSS statistics 26.0 and GraphPad Prism 8.0 software. Results: In universal analyses, the MF progression group exhibited lower hemoglobin values [105 (92-116)g/L vs 130 (119~140)g/L, P<0.001], platelet values [676 (462-798)×10^9/L vs 791 (639-1028)×10^9/L, P=0.020], hematocrit values [39 (35-42)% vs 33 (31~36)%, P<0,001], and triglyceride values [1.45(1.15-1.75)mmol/L vs 1.2(0.85-1.67)mmol/L, P=0.011]. On the contrary, it showed higher RDW values [17.2(15.6-22.2)% vs 13.9(13.1-15.3)%, P<0.001], higher uric acid values [368(265-455)U/L vs 308(249-375) U/L, P=0.013], a higher proportion of splenomegaly [82.9% vs 14.4%, P<0.001], and a higher proportion of smoking [46.2% vs 6.7%, P<0.001]. In multiple analyses, RDW>15%[OR 12.899 95% CI(3.003-55.526), P=0.001], smoking[OR 6.540 95% CI (1.943-22.013), P=0.002], splenomegaly [OR 12.442 95% CI (3.698-41.863), P<0.001], higher LDH values[OR 1.005 95% CI (1.000=1.009), P=0.036], and lower platelet values[OR 0.996 95% CI (0.994-0.999), P=0.002] were still significantly different (Figure A). Additionally, next-generation sequencing landscape was performed in 40 ET patients, in which 13 MF progression patients had identified 47 mutations of 30 different types and 27 non-MF progression patients had identified 88 mutations of 49 different types. JAK2V617F and TET2 mutation were common in non-MF progression patients (Figure C) while the mutation of ASXL1 was ranked number two in MF progression patients (Figure B). The MF progression had a higher frequency of ASXL1 mutation than the non-MF progression (38.5% vs 3.7%) (Figure D), revealed the ASXL1 mutation was a risk factor to MF progression [OR 16.250 95% CI (1.648-160.243), P=0.017]. Conclusion: Higher RDW (>15%) was an independent prognostic factor for MF progression. ET patients with ASXL1 mutation were more likely to progress into MF. Acknowledgement: This research was funded by the Key R&D Program of Zhejiang, No. 2022C03137; Public Technology Application Research Program of Zhejiang, China, No. LGF21H080003; Zhejiang Medical Association Clinical Medical Research special fund project, No. 2022ZYC-D09; the Key Project of Jinhua Science and Technology Plan, China, No. 2020-3-011.*Correspondence to: Prof Jian Huang.Keywords: Essential Thrombocytemia

ASXL1 Mutations in Chinese Patients with Essential Thrombocythemia

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia.

A Quantitive Assay and Clinical Significance for JAK2V617F Mutation in Chinese Patients with Essential Thrombocytosis

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Impact of TET2, SRSF2, ASXL1 and SETBP1 Mutations on Survival of Patients with Chronic Myelomonocytic Leukemia.

Quantitative Analysis for Jak2 Mutation in 98 Patients with Essential Thrombocythemia and Its Clinical Significance

JAK2, MPL, and CALR Mutations in Chinese Han Patients with Essential Thrombocythemia.

[Comparison of Clinical Characteristics of JAK2, CALR and Tri-Negative Driving Mutant Type in Patients with Essential Thrombocythemia]

[Clinical Characteristics and Risk Factors for Major Thrombosis in 604 Chinese Patients with Low-Risk Essential Thrombocythemia].

A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia

The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing

PB2206: PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY

Frequency and Allele Burden of CALR Mutations in Chinese with Essential Thrombocythemia and Primary Myelofibrosis Without JAK2(V617F) or MPL Mutations.

[Clinical Features and Survival Analysis in Non-M(3) Acute Myeloid Leukemia Patients with ASXL1 Gene Mutation].

[Symptomatic Profiles of 173 Chinese Patients with Essential Thrombocythemia].

Triple Gene Detection of CALR, JAK2(V617F) or MPL(W515L/K) Mutation to Predict Thrombosis and Splenomegaly Risk in Essential Thrombocythemia and Primary Myelofibrosis Patients: A Systematic Review and Meta-Analysis

Spectrum Of Gene Mutations And Clinical Significance In Myeloid Malignancies Patients With Asxl1 Mutations

Clinical Characteristics and Prognostic Study of Adult Acute Myeloid Leukemia Patients with ASXL1 Mutations

Reduced platelet activation in triple-negative essential thrombocythemia compared with JAK2V617F-mutated essential thrombocythemia

Genetic Landscape of Recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 Mutations in 304 Chinese Patients with Myelodysplastic Syndromes